Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic-guided and clinical warfarin dosing algorithm assessments with bleeding outcomes risk-stratified by genetic and covariate subgroups.

International journal of cardiology - 15 Oct 2020

Dietz Nicholas, Ruff Christian, Giugliano Robert P, Mercuri Michele F, Antman Elliott M

Abstract excerpt

BACKGROUND: Safe administration of warfarin presents challenges due to a narrow therapeutic INR range and significant variability in inter-individual dose response. Bleeding secondary to warfarin use is a leading cause of hospitalization. METHODS: Five warfarin dosing algorithms were assessed for accuracy of predicted compared to the INR target dose for patients with a HAS-BLED score ≥3 participating in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Algorithms
Share to Anticoagulants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aryl Hydrocarbon Hydroxylases

Share to Cytochrome P-450 CYP2C9

Share to International Normalized Ratio

Share to Pharmacogenetics

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Identifiers

PMID: 32505370
DOI: 10.1016/j.ijcard.2020.03.055

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic-guided and clinical warfarin dosing algorithm assessments with bleeding outcomes risk-stratified by genetic and covariate subgroups.PMID 32505370Read ↗

Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.Semantic proximity Read ↗

Warfarin Pharmacogenetics Reevaluated: Subgroup Analysis Reveals a Likely Underestimation of the Maximum Pharmacogenetic Benefit by Clinical Trials.Semantic proximity Read ↗

A pharmacogenetic versus a clinical algorithm for warfarin dosing.Semantic proximity Read ↗

Genotype-guided warfarin therapy: current status.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.Semantic proximity Read ↗

Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial.Semantic proximity Read ↗

A randomized trial of genotype-guided dosing of warfarin.Semantic proximity Read ↗

International warfarin genotype-guided dosing algorithms in the Turkish population and their preventive effects on major and life-threatening hemorrhagic events.Semantic proximity Read ↗

Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinSemantic proximity Read ↗

Efficacy and safety of genotype-guided warfarin dosing versus non-genotype-guided warfarin dosing strategies: A systematic review and meta-analysis of 27 randomized controlled trials.Semantic proximity Read ↗

Subgroup analysis of genotype guided vs traditional warfarin dosing in Asian patients from an open label randomized trial.Semantic proximity Read ↗

Meta-analysis of efficacy and safety of genotype-guided pharmacogenetic dosing of warfarin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.